The benefits of long-term opioid therapy and the evidence to support its use in managing chronic non-cancer pain are limited.1 Benzodiazepines (BZDs), when combined with prescription opioids, significantly increase the risk of overdose, as BZDs can have a synergistic effect on respiratory depression.2 Due to substantial risk of fatal overdose, higher risk of suicide, higher health service utilization, and suboptimal treatment outcomes, it is important to assess the risks and benefits of co-prescribing opioids and BZDs.3 According to a 2017 retrospective analysis, eliminating concurrent opioid and BZD use may result in an estimated 15% reduction in risk for emergency room visits and inpatient admissions related to opioid overdose.2,3 Tapering one or both medications may be an effective strategy to decrease risk and improve patient outcomes.
Tapering Considerations
Opioid Taper Tips
Opioids may be tapered using a slow or rapid taper method.6 The rate of taper may be determined by treatment history, degree of risk, and individual patient factors.6,7 Below are taper recommendations from the US Department of Health and Human Services.
Rapid Taper
Slow Taper
General Recommendations
For additional information regarding opioid tapering strategies, clinical pearls, and opioid taper examples from the Veterans Affairs, please refer to the Drug Information Group FAQ about guidance on tapering long-term opioid analgesics.
Sample Opioid Slow Taper Schedule
Benzodiazepine Taper Tips
Benzodiazepines may be tapered using a slow or rapid taper method.7 Abrupt withdrawal is not recommended, as it may lead to life-threatening events. Specific taper strategies may vary, depending on treatment history, degree of risk, and individual patient factors. Below are taper recommendations from the Oregon Pain Guidance.
Rapid Taper
Slow Taper
General Recommendations
Additional Resources for Tapering
Opioid Tapering Flow Sheet from Oregon Pain Guidance
Taper recommendations for opioids and BZDs
https://www.oregonpainguidance.org/app/content/uploads/2016/05/Opioid-and-Benzodiazepine-Tapering-flow-sheets.pdf
The National Center for Posttraumatic Stress Disorder
Prescriber considerations for BZD taper
https://www.va.gov/painmanagement/docs/OSI_6_Toolkit_Taper_Benzodiazepines_Clinicians.pdf
The Veterans Health Administration
BZD dose conversion chart and sample tapering schedule
https://www.pbm.va.gov/PBM/AcademicDetailingService/Documents/Benzodiazepine_Provider_AD_%20Risk_Discussion_Guide.pdf
Summary
Several risks are associated with the concurrent use of benzodiazepines and opioids. Tapering one or both medications may be necessary to reduce these risks. Set specific goals and follow-up visits before implementing a taper plan. Support patients with pain by offering alternative therapies during an opioid taper (ie, non-pharmacologic and non-opioid medications) for effective pain management during and after the taper. During a BZD taper, consider optimization of first-line agents for any underlying disorder. Use supportive medications to alleviate withdrawal symptoms during the taper process. Effective and successful tapering can improve a patient’s quality of life and often requires collaboration between prescribers and patients.
Prepared by:
Liana Osis, PharmD
Clinical Pharmacist, Academic Detailer
University of Illinois Chicago College of Pharmacy
Tara Gallagly, PharmD
Clinical Pharmacist, Academic Detailer
University of Illinois Chicago College of Pharmacy
Nerissa Caballes, PharmD, MS, CRC
Assistant Director, Academic Detailer
University of Illinois Chicago College of Pharmacy
The information presented is current as of August 12, 2022. This information is intended as an educational piece and should not be used as the sole source for clinical decision making.